Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Stu
Go back to Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Stu| (NASDAQ: ROIV) | Delayed: 39.57 +0.07 (0.18%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $39.50 | 52 Week High | $ | |||
| Open | $39.77 | 52 Week Low | $ | |||
| Day High | $40.45 | P/E | N/A | |||
| Day Low | $39.17 | EPS | $ | |||
| Volume | 6,181,217 | |||||
